Convergen Secures $15 Million Seed+ Financing to Advance Therapeutics for Protein Aggregation Diseases

PR NewswireAug 31, 2026 1:00 PM

View all comments（0）



SUZHOU, China, Aug. 31, 2026 /PRNewswire/ -- Convergen, a biotechnology company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, today announced the closing of a $15 million Seed+ financing round. This round was led by MPCi, with participation from LAV, BioTrack Capital and a leading biotech fund. Prior to this round, the company raised $10 million in a seed financing round led exclusively by Qiming Venture Partners.

The proceeds will be used to further advance Convergen's proprietary degrader platform and accelerate its pipeline for neurodegenerative disorders and other protein aggregation diseases.

"We are grateful to the distinguished group of investors and their confidence in our science, platform and team," said Dr. Jinquan Sun, CEO of Convergen. "We have made significant progress in advancing our protein degradation platform. This financing will enable us to accelerate our lead asset toward the clinic while continuing to advance our pipeline, with the goal of bringing new therapeutic options to patients with neurodegenerative diseases and beyond."

Addressing a Critical Unmet Need
Neurodegenerative diseases such as Alzheimer's represent one of the largest unmet medical needs globally, with pathologic protein aggregation at the core. Convergen's scientific founder Prof. Ting Han, whose laboratory reported the first TRIM21 molecular glue, established the proof-of-concept of the first TrimTAC degrader (November 2024 in Cell) which targets protein aggregopathies by exploiting TRIM21's unique property. Beyond neurodegeneration, TrimTAC has demonstrated potential in selectively degrading other targets for autoimmune diseases.

MPCi said:
"Convergen's degrader platform is truly differentiated in the targeted protein degradation landscape. Matrix Partners China has long adhered to an investment philosophy of 'investing early, investing in high barriers, and investing in differentiation,' with a focus on the application potential of breakthrough technology platforms across disease areas. We are highly confident in the extensibility of Convergen's original platform and in the team's ability to translate scientific discovery into clinical drugs. We look forward to partnering with the company to advance novel therapeutic options to patients worldwide."

About Convergen
Convergen is a biotechnology company pioneering the next-generation targeted protein degradation technology designed to selectively eliminate pathological protein aggregates. Founded to address the significant unmet medical needs in neurodegenerative disease and beyond, the company combines cutting-edge academic research with industry-proven drug development expertise.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

US Stocks Mixed as Dow Drops 160 Points; Tech Stocks Lead, Meta Rises 4.5%

The top leaders of China and the U.S. met in the United States, alongside reports that U.S.-Iran negotiations were seeking to reopen the Strait of Hormuz. U.S. stocks recovered part of their losses, with technology stocks leading the gains. At the close, the Dow Jones Industrial Average fell 0.31% to 51,349.98; the Nasdaq Composite Index rose 0.01% to 26,939.37; and the S&P 500 Index dipped 0.02% to 7,704.13.

Meta Stock Forecast: Muse Monetization Path Is Key as JPMorgan Raises Price Target to $920; Can Stock Hit Record High?

On September 24, Eastern Time, Meta Platforms (META) reached an intraday price of $777.89, hitting a nearly one-year high. Following the Meta Connect event, JPMorgan raised its price target on the company from $820 to $920 while maintaining an Overweight rating. The core reason is that the monetization path for Muse is becoming increasingly clear, leaving the bank more optimistic about Meta's growth potential beyond advertising.

Oracle Tumbles 7% as Project Jupiter Data Center Force Majeure Notice Sparks Delay Concerns

On September 24, Oracle (ORCL) fell as much as 5% in pre-market trading and dropped over 7% after the market opened. Sparking market concerns was a force majeure notice issued by the company regarding Project Jupiter, a large-scale data center in New Mexico. Investors' focus is shifting from massive AI orders to delivery timelines and capital recovery. According to Bloomberg, Oracle has sent a formal notice to developer Stack Infrastructure, seeking to delay payments if the project fails to become operational as planned in 2028. This move does not imply exiting its position as the primary tenant, nor does it mean a payment waiver has been granted. Oracle maintained that the project is proceeding according to schedule, but did not specifically address the notice itself.

Meta Connect 2026 New Product Roundup: Muse Integrated Into AI Glasses, Can It Drive Meta Revenue Growth?

TradingKey - At the Connect 2026 conference held from September 23 to 24, Meta (META) unveiled the Ray-Ban Meta Audio, third-generation Ray-Ban Meta, and Meta VR Glasses, while upgrading the Meta Ray-Ban Display. The company also announced the integration of its personal AI agent, Muse, into its AI glasses, expanding its product scope from mobile phones and social apps to wearable devices.

The Week Ahead: US-China Summit in Washington, Costco Earnings and Fed Rate Path in Focus

TradingKey - During the week of September 21 to 25, Eastern Time, the US stock market will focus on the meeting between Chinese and US leaders, the Federal Reserve's policy outlook, and economic data such as US new home sales and durable goods orders.

Featured Tools